Evidence map›Paper›PMID 42103895›Full record

ArticleCell death and differentiation2026

m

Changzhi Li, Xianchao Tang, Zimi Zeng, Liqian Yang, Fang Cao, Haiyan Zhu, Liqing Zhu, Jie Shen, Xiaocui Bian, Libin Wang and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Changzhi Li *Department of Biochemistry and Molecular Biology, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Xianchao Tang *Department of Pathology, Cell Resource Center, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zimi Zeng *Department of Biochemistry and Molecular Biology, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Liqian YangDepartment of Biochemistry and Molecular Biology, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Fang CaoKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China.
Haiyan ZhuDepartment of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China.
Liqing ZhuDepartment of Clinical Laboratory, Peking University Cancer Hospital & Institute, Beijing, China.
Jie ShenDepartment of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Xiaocui BianDepartment of Pathology, Cell Resource Center, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.ORCID http://orcid.org/0000-0003-1960-8465
Libin WangDepartment of Cell Biology, School of Basic Medical Sciences, Peking University Stem Cell Research Center, Peking University Health Science Center, Peking University, Beijing, China.
Yang LiuDepartment of Medical Genetics, Center for Medical Genetics, School of Basic Medical Sciences, Peking University Health Science Center, Peking University, Beijing, China.ORCID http://orcid.org/0000-0002-5058-7781
Fengbiao MaoInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.ORCID http://orcid.org/0000-0003-0852-4266
De ChangCollege of Pulmonary and Critical Care Medicine, 8th Medical Center, Chinese PLA General Hospital, Beijing, China.
Pengtao JiaoInstitute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing, China. pengtaojiao66@126.com.
Haiying WangDepartment of Biochemistry and Molecular Biology, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China. wendy@bjmu.edu.cn.ORCID http://orcid.org/0000-0001-7729-0649
Kailong LiDepartment of Biochemistry and Molecular Biology, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China. kailongli@pku.edu.cn.ORCID http://orcid.org/0000-0001-5369-354X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82273131
6 · The paper itself

Abstract

Radiotherapy is a mainstay of cancer treatment, yet its efficacy is still substantially restricted due to radioresistance. The mechanisms underlying radioresistance remain elusive, impeding drug development and therapeutics. Here, using a high-throughput random gene perturbation method based on piggyBac transposon, we screened and identified CABLES1, an adaptor protein, as a key regulator of tumor radioresistance. The function of CABLES1 in radioresistance was further validated in multiple human cell lines in vitro and a mouse xenograft model in vivo. High expression of CABLES1 is significantly correlated with radioresistance in cancer patients. Mechanistically, CABLES1 interacts with XRCC6/XRCC5 heterodimer and activates DNA-PKcs by promoting DNA-PK holoenzyme formation, thus facilitating the efficiency of nonhomologous end-joining (NHEJ) repair and radioresistance. Notably, YTHDF1 recognizes METTL14-deposited m

Identifiers

PMID42103895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.